Damora Therapeutics (DMRA) traded up 0.81 % during a 24 hours period ending at 01:27 PM Central Europe on Tuesday 27th. One Damora Therapeutics stock can currently be bought for about USD 21.26 on popular exchanges. Current supply of Damora Therapeutics stocks is 61.8 mn. Damora Therapeutics has a current market capitalization of USD 1.3 bn and approximately USD 13.6 mn worth of Damora Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Damora Therapeutics has traded 2.46 % up. Simple moving average of last 200 days is at USD 25.67. The highest price of past 52 weeks was recorded at USD 38.32 on 12/26/2025. 52 weeks low was at USD 4.95 on 11/07/2025.
Here is how related stocks have performed in the past 24 hours:
Intellia Therapeutics (NTLA) traded up 0.45 % and now trades at USD 11.26. Intellia Therapeutics has a market capitalisation of USD 1.6 bn.
Phibro Animal Health (PAHC) traded up 0.59 % and now trades at USD 39.03. Phibro Animal Health has a market capitalisation of USD 1.6 bn. Current price/earnings ratio for Phibro Animal Health is 16.05.
Certara (CERT) traded up 2.71 % and now trades at USD 10.61. Current market capitalisation for Certara is USD 1.6 bn.
Absci (ABSI) traded up 2.94 % and now trades at USD 9.45. Absci has a market capitalisation of USD 1.6 bn.
First Tracks Biotherapeutics (TRAX) traded down -1.29 % and now trades at USD 43.48. First Tracks Biotherapeutics has a market capitalisation of USD 1.6 bn. First Tracks Biotherapeutics, Inc. has filed a registration statement on Form S‑1 with the U.S. Securities and Exchange Commission, detailing the company’s status as an emerging growth and smaller reporting company. The filing outlines a private placement of 6.1 million shares of common stock, valued at roughly $200 million before expenses, completed on October 15 2026. The company will not receive proceeds from the resale of these shares, which are to be offered by the selling stockholders under a registration rights agreement that requires the company to file a subsequent registration statement. The prospectus describes the company’s clinical‑stage pipeline of antibody therapies for autoimmune and inflammatory diseases, including candidates in early‑phase trials. It highlights the potential for regulatory, development, and market risks, noting that product candidates may fail or experience delays that could affect commercial viability. The company’s common stock, listed on Nasdaq under the ticker “TRAX,” has experienced volatility, and the filing cautions that large secondary sales could further impact the share price. The update reflects the company’s current capital‑raising activity and outlines the broader regulatory and development challenges facing its product pipeline.
About Damora Therapeutics
Galecto, Inc. is a clinical stage biotechnology company based in Copenhagen, Denmark. The company specializes in developing small molecules for the treatment of severe diseases such as fibrosis, cancer, and inflammation. Gallecto serves customers globally and can be accessed through their website at www.galecto.com . The company’s stock is traded on the Nasdaq.